Avecia

Last updated

Avecia, a part of Nitto Denko Inc., is a private biotechnology company focused on oligonucleotide production. [1] Avecia has two facilities, one near Boston, MA, and the second in Cincinnati, OH. [1] In 2016 Avecia acquired the assets of Irvine Pharmaceutical Services and Avrio Biopharmaceuticals. [2] Avecia was organized with a biologics business line and the oligonucleotide business line. In 2009, Avecia Biologics Limited based in Billingham, UK was acquired by Merck and was later part of Fujifilm Diosynth Biotechnologies. [3]

References

  1. 1 2 Kansteiner, Fraiser (March 31, 2021). "Nitto Denko lays out $226M to boost oligonucleotide production in a bustling RNA market". Fierce Pharma. Retrieved June 3, 2024.
  2. ↑ "Nitto Denko Avecia Inc acquires businesses of Irvine Pharmaceutical Services, Avrio Biopharmaceuticals". Reuters . October 11, 2016. Retrieved June 3, 2024.
  3. ↑ "Merck & Co., Inc. to Acquire Avecia Biologics | Fierce Biotech". www.fiercebiotech.com. 17 December 2009.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.